CPA
HRTX icon

Capital Performance Advisors’s Heron Therapeutics HRTX Stock Holding History

Capital Performance Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,242
Closed -$2.47K – 1279
2024
Q3 		$2.47K Buy
+1,242
New +$2.97K ﹤0.01% 1468

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Capital Performance Advisors's HRTX Position: Q4 2024 in Review

Capital Performance Advisors sold out of Heron Therapeutics (HRTX) in Q4 2024, closing a stake of 1,242 shares — an estimated $2.47K sold.

Capital Performance Advisors first reported a position in HRTX in Q3 2024 and held it in 1 quarter. The position peaked at $2.47K in Q3 2024. 161 funds tracked by Wall St. Rank hold HRTX as of Q4 2024.

  • Capital Performance Advisors reported no remaining Heron Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 1,242 Heron Therapeutics shares in Q4 2024, an estimated $2.47K.
  • Capital Performance Advisors first reported a position in Heron Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Heron Therapeutics position peaked at $2.47K in Q3 2024.
  • 161 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.